

Is HbA1c an ideal biomarker of well-controlled diabetes?

Georgia Kaiafa ¹, Stavroula Veneti,¹ George Polychronopoulos,¹ Dimitrios Pilalas,¹ Stylianos Daios,² Ilias Kanellos,¹ Triantafyllos Didangelos,¹ Stamatina Pagoni,^{3,4} Christos Savopoulos ¹

► Supplemental material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/postgradmedj-2020-138756>).

¹First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Greece

²Internal Medicine Department, General Hospital of Serres, Greece

³3rd Department of Internal Medicine, "G. Gennimatas" General Hospital of Athens, Greece

⁴Hellenic Society of Internal Medicine, Athens, Greece

Correspondence to

Georgia D Kaiafa, First Propedeutic Department of Internal Medicine, AHEPA University Hospital, Thessaloniki 54636, Greece; gdkaiafa@yahoo.gr

Received 23 July 2020

Accepted 15 August 2020

Published Online First 10 September 2020

ABSTRACT

HbA1c is a biomarker with a central role in the diagnosis and follow-up of patients with diabetes, although not a perfect one. Common comorbidities encountered in patients with diabetes mellitus, such as renal insufficiency, high output states (iron deficiency anaemia, haemolytic anaemia, haemoglobinopathies and pregnancy) and intake of specific drugs could compromise the sensitivity and specificity of the biomarker. COVID-19 pandemic poses a pressing challenge for the diabetic population, since maintaining optimal blood glucose control is key to reduce morbidity and mortality rates. Alternative methods for diabetes management, such as fructosamine, glycosylated albumin and device-based continuous glucose monitoring, are discussed.

1. INTRODUCTION

Blood glucose regulation is a key factor for an effective immune response against infections and that is the main reason why diabetics have 4.4 times greater risk of systemic infection than non-diabetics.^{1–3} In the current SARS-CoV-2 setting optimal glucose control is of utmost importance in order to avoid excess morbidity and mortality and to optimise healthcare resource allocation. Furthermore, according to recent data, diabetic COVID-19 patients are at higher risk of severe pneumonia, hospitalisation and adverse clinical outcomes including increased mortality.^{4–6} Subsequently, accurate biomarkers for diagnosis and follow-up of diabetes mellitus (DM) are particularly relevant in the current setting. Glycosylated haemoglobin (HbA1c) has a central role in diabetes diagnosis and monitoring.

The aim of the current paper is to address the role and the limitations of HbA1c in specific patient populations.

2. ASSESSMENT OF HbA1c

Allen first recognised HbA1c in 1958 as component of human haemoglobin (Hb), while 10 years later Rahbar demonstrated the presence of an 'abnormal' Hb in diabetic patients. In 1970, the first application of HbA1c was made, followed by the appearance of the first available method to measure HbA1c levels. In 1993, the importance of HbA1c in the prognosis of DM related complications was demonstrated, and in 2010 HbA1c $\geq 6.5\%$ was established as a diagnostic criterion for DM by the American Diabetes Association (ADA).⁷

It is well known that glycosylation of Hb is achieved by glucose entering the erythrocyte through the GLUT1 transporter and its connection to the amino acid valine which is located at the N-terminal of the beta chain of Hb. This procedure leads in the creation of a Schiff base resulting in the formation of a stable Amadori product, which is known as HbA1c.⁸

HbA1c is useful in the diagnosis, prevention and monitoring of DM, reflecting the impact of lifestyle and medication on glycaemic control over the past 3 months. Moreover, HbA1c levels between 5.7% and 6.4% correspond to people with pre-diabetes who are at higher risk of developing DM.⁹ Intensive glycaemic control and lower levels of HbA1c are followed by reduction of diabetic complications; at HbA1c $< 7\%$, there is a 76% reduction in the incidence of diabetic retinopathy, 54% of diabetic nephropathy, 60% of peripheral neuropathy and 35% of cardiovascular disease risk.¹⁰ On the other hand, lowering HbA1c levels is associated with higher risk of hypoglycaemia prevalence among patients with type 1 and type 2 diabetes. Several studies have demonstrated a negative relationship between HbA1c and hypoglycaemia in diabetic patients.^{11 12}

Measurement of HbA1c should comply with international methods in the absence of conditions that may interfere with the results.¹³ There are two basic principles of HbA1c measurement: either with separation of HbA1c from other Hb fractions by chromatography and electrophoresis, or by targeting HbA1c as an antigen with immunochemistry. More specifically, there are four methods of measurement: (i) ion-exchange high-performance liquid chromatography (HPLC), (ii) boronate affinity HPLC, (iii) immunoassay and (iv) enzymatic assays. Affinity chromatography measures total HbA1c and is less affected by the presence of Hb variants, but does not separate HbA1c species and overestimates its values, while immunoassays are affected by high HbF values. In particular, at the end of the beta chain of HbF molecule, there is glycine instead of valine, which is acetylated thus contributing to an underestimation of HbA1c levels by almost 20%.¹⁴ As a result, it was considered necessary for HbA1c measurement methods to be standardised and so in 1996, the National Glycohemoglobin Standardization Program (NGSP) was introduced, which measures HbA1c in percentage and later in 2001 the International Federation of Clinical Chemistry



© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Kaiafa G, Veneti S, Polychronopoulos G, *et al.* *Postgrad Med J* 2021;**97**:380–383.

and Laboratory Medicine (IFCC) which measures HbA1c in mmol HbA1c/mmol Hb and the estimated average glucose (eAG), which is not particularly used. IFCC reference values—due to their greater specificity—are 1.5–2% units below NGSP values, time consuming and not widely used in clinical practice.⁸ It is accepted that any change in HbA1c value by at least 0.5% in a laboratory certified by NGSP is considered statistically and clinically significant, while any change about 1% of HbA1c is associated with a ~30 mg/dL change in plasma glucose levels.⁸

In comparison with other methods of DM diagnosis, HbA1c measurement may have a higher cost but does not require fasting before measurement and it is not affected by stressful situations or the acute phase of the disease.¹⁵ If the sample cannot be measured immediately, it can be maintained safely either at 2–8°C for 4 weeks or at room temperature for 2 weeks.¹⁶

It has been established that patients with same HbA1c values may have true average glucose concentrations that differ by more than 60 mg/dL.¹⁷ A mathematical model that contributes to the improvement of the accuracy of average glucose estimation from HbA1c has recently been developed. This model is based on the combination of haemoglobin glycation and red blood cell kinetics with successive patient glucose measurements to extract patient-specific estimates of non-glycaemic determinants of HbA1c, including mean erythrocyte age.¹⁷

3. DIAGNOSTIC PITFALLS OF HBA1C

The data in the literature remain conflicting with regard to the establishment of the most suitable diagnostic test of DM. Although HbA1c has been recognised by few studies as equivalent or superior screening test compared with fasting plasma glucose (FPG) and as valuable as the oral glucose tolerance test (OGTT), there have been also studies with opposite results.¹⁸ Estimated glycaemic control with HbA1c alone may not be completely accurate in some diabetics and does not properly affect treatment decisions.¹⁹ In any case, the application of all three ways of glucose estimation contributes to the better identification of individuals who are likely to develop DM.

It is already known that HbA1c values fluctuate even in non-diabetic individuals (in healthy population only 50% of HbA1c fluctuations are affected by glucose levels).²⁰ In particular, the HbA1c value may be affected by changes in the amount of glucose that penetrates the erythrocyte membrane, by a change in the rate of glycosylation or by a change in the erythrocyte's lifespan. Any condition that prolongs or shortens the lifespan of erythrocytes or is associated with a reduced or increased rate of regeneration, exposes the erythrocytes for longer or shorter duration to the effect of glucose, resulting in an increased or decreased HbA1c value, respectively.⁹ Moreover, there is a large heterogeneity in the lifespan of red blood cells in haematologically healthy individuals. Older red blood cells have already been glycosylated to a greater extent than younger ones, while younger ones are more numerous and have an average half-life of about 30 days. Half of the result of a given HbA1c measurement is due to the contribution of erythrocyte glycosylation over the last 30 days, while glycosylation of red blood cells aged 90–120 days reflects only the 10% of the HbA1c value.²¹ Other factors that affect HbA1c in healthy population include age as there is a 0.1% increase in HbA1c for every 10 years, race (0.1–0.4% decrease in HbA1c has been observed in Caucasians compared with non-Caucasian populations for the same glucose levels) and pregnancy, because there is a reduced lifespan of erythrocytes from 120 to 90 days, with

low HbA1c values in the second trimester, plateau at 20–24 weeks and increase in the third trimester.¹

Improper glycaemic control reduces erythrocyte lifespan because the permeability of the erythrocyte membrane changes, the shape of red blood cells is distorted and the amount of sorbitol in red blood cells increases, which dramatically affects the activity of NA-KATPase resulting in erythrocyte destruction. In addition, red blood cells of patients with DM have a higher phosphatidylserine content in the erythrocyte membrane and this contributes to their better recognition and destruction by the reticuloendothelial system.²²

Several factors that could lead to false increase or false decrease in levels of HbA1c are summarised in online supplemental table 1.

3. 1. False increase

Conditions that prolong the lifespan of red blood cells such as iron deficiency anaemia, B₁₂ and folic acid deficiency anaemia due to reduced erythrocyte proliferation or functional asplenia due to decreased destruction of blood cells could falsely increase HbA1c levels.¹⁶ Severe hypertriglyceridaemia (>1750 mg/dL), severe hyperbilirubinaemia (>20 mg/dL) and uraemia (due to carbaminohaemoglobin) also constitute commonly reported conditions associated with falsely elevated HbA1c. Alcohol intake due to the creation of a complex with acetaldehyde may cause false increase of HbA1c levels. Furthermore, several drugs and substances have been reported to interfere with HbA1c levels such as salicylates, opioids and lead poisoning.¹⁶

3. 2. False decrease

On the other hand, there are conditions that cause falsely decreased levels of HbA1c such as anaemia due to blood loss, or haemolytic anaemia by shortening the lifespan of erythrocytes, and splenomegaly as it leads to increased red cell turnover.²³ Pregnancy also results in false decrease of HbA1c levels because of the decreased life span of the red blood cells. Moreover, the use of vitamin E, ribavirin, interferon A, cephalosporins, levofloxacin, penicillins, anti-inflammatory drugs and quinine (may cause haemolytic anaemia) has been associated with falsely decreased HbA1c levels.^{16 23}

It is worth mentioning the controversial effect of vitamin C on HbA1c levels which is often used over the counter as component of vitamin supplements especially in the era of COVID-19 pandemic. Randomised clinical trials (RCTs) testing the effects of vitamin C on several biomarkers of glucose control such as HbA1c have reported variegated findings. A metaanalysis and systematic review by Ashor *et al* demonstrated that HbA1c concentration was not modified by vitamin C supplementation.²⁴ Moreover, the data synthesis from five RCTs of vitamin C administration revealed a significant reduction in glucose levels without a significant effect on HbA1c levels.²⁵ However, previously published metaanalysis reported a significant decrease in HbA1c levels.²⁶

Furthermore, HbA1c is not reliable in patients suffering from homozygous haemoglobinopathy, while in heterozygous forms there is reliability depending on the measurement method. Presence of haemoglobinopathy should be suspected when there is a discrepancy between the HbA1c value and the patient's daily glucose measurements, when HbA1c >15%, when there is a significant difference in HbA1c compared with previous values and when there is anaemia with abnormal red cell indices. In hereditary persistence of HbF, either in homozygous or in heterozygous form, falsely lower HbA1c values have been observed.²⁷

Patients with end-stage renal disease present falsely decreased HbA1c values due to reduced proliferation rate and differentiation of erythrocyte precursor cells and ineffective response to endogenous erythropoietin (anaemia of chronic disease). Additional factors such as use of erythropoietin injections and uraemia could also modify HbA1c levels. In these patients, glycaemic control should be monitored with other methods except HbA1c, such as the measurement of fructosamine and glycosylated albumin (these methods estimate the glycaemia of the last 3 weeks because the half-life of albumin is 14–20 days).²⁸ In diabetic haemodialysis patients, the measurement of glycosylated albumin is more reliable than the measurement of HbA1c, and in fact values of glycosylated albumin between 15.6% and 18.2% are considered to be associated with lower annual mortality. Moreover, it is known that in this group of patients the measurement of glycosylated albumin shows a much lower percentage of the burnt-out diabetes phenomenon.²⁹ Nevertheless, diagnostic pitfalls in the measurements of fructosamine and glycosylated albumin may occur in cases of hypoproteinaemia, such as cirrhosis and nephrotic syndrome, and also in hyperlipidaemia.

4. ALTERNATIVE METHODS OF ESTIMATING GLYCAEMIA

Another method of estimating glycaemia over the last 48 hours to 2 weeks is to measure 1.5-anhydroglucitol (1.5-AG), which essentially reflects postprandial glycaemia. Limitations include renal, hepatic insufficiency and pregnancy.³⁰

Finally, continuous glucose monitoring (CGM), which reflects glucose in the interstitial space and shows glycaemic levels of the last 3–7 days, is an additional way to measure glucose, especially for the treatment of high-risk diabetic patients, such as those with stroke or acute coronary syndrome, in which fasting glucose and oral glucose tolerance could provide safe information only 4 days after the acute episode, because during this time there is intense activation of the sympathetic nervous system and insulin resistance.^{31–32} CGM method emerges as a very valuable tool improving safety and effectiveness of diabetes treatment, reducing hypoglycaemia and decreasing glycaemic variability.³³ More specifically time in range (TIR) of 70–180 mg/dL (3.9–10 mmol/L) derived from CGM devices has been proven as a significant index of glycaemia which reflects microvascular and macrovascular complications and it can supplement HbA1c outcomes.³⁴

Although for several decades intensive glycaemic control has been the predominant target for the treatment of diabetic patients, studies have shown that achieving a HbA1c <7% was not associated with additional cardiovascular benefit, shifting the goal of DM treatment to reducing the risk of developing diabetic complications rather than achieving of lower glycaemic levels.³⁵ Nevertheless, HbA1c remains unquestionably a very important method for assessing glycaemic control in diabetics (long-term glycaemic control and risk of developing complications), while the other methods (fructosamine, glycosylated albumin, 1.5-AG and CGM) are used to supplement the data, resulting from HbA1c measurements and in situations where HbA1c results are considered precarious.

In the absence of a formula to correct the discrepancies in the observed HbA1c values and the glycaemic status in specific patient populations, the physicians managing diabetes mellitus should follow an individualised approach to ensure optimal treatment. In the current pandemic milieu, uncontrolled diabetes has been associated with worse outcomes in COVID-19 patients.^{36–37} Thus, extra caution is warranted when assessing glycaemic control with HbA1c in patients with the aforementioned comorbidities, as a modifiable risk factor may go unchecked.

Main messages

1. HbA1c should be interpreted with caution in patients with frequently encountered comorbidities.
2. Chronic kidney disease, functional asplenia, iron, B12 and folic acid deficiency anaemia are among the conditions associated with falsely increased HbA1c levels.
3. Pregnancy and conditions such as splenomegaly, anaemia due to blood loss and haemolytic anaemia are associated with falsely decreased HbA1c levels.
4. Alternative biomarkers (fructosamine, glycosylated albumin, 1.5-anhydroglucitol) and methods such as continuous glucose monitoring may be more reliable in specific situations.

Self-assessment questions

1. Which of the following factors could lead to falsely increased levels of HbA1c?
 - a. Functional asplenia.
 - b. Splenomegaly.
 - c. Chronic alcohol intake.
 - d. Iron deficiency anaemia.
2. Which of the following factors could lead to falsely decreased levels of HbA1c?
 - a. Haemolytic anaemia.
 - b. Pregnancy.
 - c. Chronic kidney disease.
 - d. B₁₂ deficiency anaemia.
3. Which of the following methods are the most suitable for estimating glycaemia in patients with acute stroke?
 - a. HbA1c.
 - b. Fasting glucose.
 - c. Continuous glucose monitoring.
 - d. Oral glucose tolerance test.
4. Which of the following methods are the most suitable for estimating glycaemia in patients with end-stage renal disease?
 - a. HbA1c.
 - b. Glycosylated albumin.
 - c. Fructosamine.
 - d. Oral glucose tolerance test.
5. Which of the following factors affect HbA1c values in non-diabetic individuals?
 - a. Height.
 - b. Age.
 - c. Race.
 - d. Pregnancy.

Current research questions

1. Is HbA1c an ideal biomarker of well-controlled diabetes?
2. Is HbA1c measurement helpful in patients with many comorbidities?
3. Is uncontrolled diabetes associated with worse outcomes in COVID-19 patients?

Contributors GDK conceived the paper. GP, DP, SD, IK performed the literature review and SV wrote the first draft which was then discussed with GK, TD, SP, CS. All authors provided critical feedback, helped shape and approved the final manuscript. GK is the guarantor.

Key references

1. d'Emden MC, Shaw JE, Jones GR, *et al.* Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus. *Med J Aust* 2015;203:89–90. doi:10.5694/mja15.00041
2. Little RR, Roberts WLA. Review of variant hemoglobins interfering with hemoglobin A1c measurement. *J Diabetes Sci Technol* 2009;3:446–51. doi:10.1177/193229680900300307
3. Sacks DB. A1C versus glucose testing: a comparison. *Diabetes Care* 2011;34:518–23. doi:10.2337/dc10-1546
4. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. *J Gen Intern Med* 2014;29:388–94. doi:10.1007/s11606-013-2595-x
5. Beck RW, Connor CG, Mullen DM, *et al.* The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. *Diabetes Care* 2017;40:994–9. doi:10.2337/dc17-0636

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the COVID-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iDs

Georgia Kaiafa <http://orcid.org/0000-0001-8000-4500>

Christos Savopoulos <http://orcid.org/0000-0002-7970-2464>

REFERENCES

1. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. *Diabetes Care* 2019;42:S13–28.
2. Van den Berghe G, Wouters P, Weekers F, *et al.* Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001;345:1359–67.
3. Burekovic A, Bostandzic AD, Godinjak A. Poorly regulated blood glucose in diabetic patients: predictor of acute infections. *Med Arch* 2014;68:163–6.
4. Guo W, Li M, Dong Y, *et al.* Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev* 2020;e3319.
5. Katulanda P, Dissanayake HA, Ranathunga I, *et al.* Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature key points. *Diabetologia* 2020;14:1–13.
6. Muniyappa R, Section CE, Branch O, *et al.* Perspective: COVID-19 pandemic, corona viruses, and diabetes Mellitus Ranganath Muniyappa and Sriram Gubbi Clinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, 2020.
7. Gillery P. A history of HbA1c through clinical chemistry and laboratory medicine. *Clin Chem Lab Med* 2013;51.
8. Ang SH, Thevarajah M, Alias Y, *et al.* Current aspects in hemoglobin A1c detection: a review. *Clin Chim Acta* 2015;439:202–11.
9. Hare MJL, Shaw JE, Zimmet PZ. Current controversies in the use of haemoglobin A1c. *J Intern Med* 2012;271:227–36.
10. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. *Diabetes Care* 2014;37:9–16.

11. Yu S, Fu AZ, Engel SS, *et al.* Association between hypoglycemia risk and hemoglobin A1c in patients with type 2 diabetes mellitus. *Curr Med Res Opin* 2016;32:1409–16.
12. Van BCAJ, Caris MG, Devries JH, *et al.* Journal of diabetes and its complications the relation between HbA1c and hypoglycemia revisited; a secondary analysis from an intervention trial in patients with type 1 diabetes and impaired awareness of hypoglycemia. *J Diabetes Complications* 2018;32:100–3.
13. d'Emden MC, Shaw JE, Jones GR, *et al.* Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus. *Med J Aust* 2015;203:89–90.
14. Little RR, Roberts WLA. Review of variant hemoglobins interfering with hemoglobin A1c measurement. *J Diabetes Sci Technol* 2009;3:446–51.
15. Sacks DB. A1C versus glucose testing: a comparison. *Diabetes Care* 2011;34:518–23.
16. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. *J Gen Intern Med* 2014;29:388–94.
17. Malka R, Nathan DM, Higgins JM. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. *Sci Transl Med* 2016;130.
18. Pajunen P, Peltonen M, Eriksson JG, *et al.* HbA1c in diagnosing and predicting type 2 diabetes in impaired glucose tolerance: the Finnish diabetes prevention study. *Diabet Med* 2011;28:36–42.
19. Beck RW, Connor CG, Mullen DM, *et al.* The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. *Diabetes Care* 2017;40:994–9.
20. Yudkin JS, Forrest RD, Jackson CA, *et al.* Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. *Diabetologia* 1990;33:208–15.
21. Cohen RM, Franco RS, Khera PK, *et al.* Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. *Blood* 2008;112:4284–91.
22. Virtue MA, Furne JK, Nuttall FQ, *et al.* Relationship between GHB concentration and erythrocyte survival determined from breath carbon monoxide concentration. *Diabetes Care* 2004;27:931–5.
23. Garbe E, Andersohn F, Bronder E, *et al.* Drug induced immune haemolytic anaemia in the Berlin case-control surveillance study. *Br J Haematol* 2011;154:644–53.
24. Ashor AW, Werner AD, Lara J, *et al.* Effects of vitamin C supplementation on glycaemic control: a systematic review and meta-analysis of randomised controlled trials. *Eur J Clin Nutr* 2017;71:1371–80.
25. Tabatabaei-malazy O, Nikfar S, Larijani B, *et al.* Influence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials; a systematic review with meta-analysis. *Pharm Sci* 2014;17:554–82.
26. Akbar S, Bellary S, Griffiths HR. Dietary antioxidant interventions in type 2 diabetes patients: a meta-analysis. *Br J Diabetes Vasc Dis* 2011.
27. Rohlfing CL, Connolly SM, England JD, *et al.* The effect of elevated fetal hemoglobin on hemoglobin A1c results. *Am J Clin Pathol* 2008;129:811–4.
28. Rhee CM, Leung AM, Kovesdy CP, *et al.* Updates on the management of diabetes in dialysis patients. *Semin Dial* 2014;27:135–45.
29. Abe M, Hamano T, Hoshino J, *et al.* Is there a "burnt-out diabetes" phenomenon in patients on hemodialysis? *Diabetes Res Clin Pract* 2017;130:211–20.
30. Kim WJ, Park C-Y. 1,5-Anhydroglucitol in diabetes mellitus. *Endocrine* 2013;43:33–40.
31. Battelino T, Danne T, Bergenstal RM, *et al.* Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. *Diabetes Care* 2019;42:1593–603.
32. Savopoulos C, Kaiafa G, Kanellos I, *et al.* Is management of hyperglycaemia in acute phase stroke still a dilemma? *J Endocrinol Invest* 2017;40:457–62.
33. Cappon G, Vettoretti M, Sparacino G, *et al.* Continuous glucose monitoring sensors for diabetes management: a review of technologies and applications. *Diabetes Metab J* 2019;43:383–97.
34. Beck RW, Bergenstal RM, Riddleworth TD, *et al.* Validation of time in range as an outcome measure for diabetes clinical trials. 2018:1–6.
35. Lipska KJ, Krumholz HM. Is hemoglobin A1c the right outcome for studies of diabetes? *JAMA* 2017;317:1017.
36. Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. *Rev Med Virol* 2020;30:2103.
37. Critchley JA, Carey IM, Harris T, *et al.* Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. *Diabetes Care* 2018;41:2127–35.

Answers

1. a) True; b) False; c) True; d) True
2. a) True; b) True; c) False; d) False
3. a) False; b) False; c) True; d) False
4. a) False; b) True; c) True; d) False
5. a) False; b) True; c) True; d) True